(Total Views: 107)
Posted On: 10/22/2023 3:10:47 PM
Post# of 9

$SNYNF News Article - Press Release: Dupixent (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE) https://marketwirenews.com/news-releases/pres...21825.html


My Twitter: WhyteStocks